Atenolol in the treatment of essential hypertension during pregnancy.

Authors:
  • PRPc Rubin
    Pc Rubin
  • LBL Butters
    L Butters
  • RLRa Low
    Ra Low
  • JRJl Reid
    Jl Reid

Abstract
Atenolol has been studied prospectively in the management of ten patients with essential hypertension during pregnancy. Median supine BP fell significantly from 156/98 mmHg before treatment to 128/82 mmHg at term. Atenolol did not suppress cardiotocographic signs of foetal distress. Although there was one intrauterine death, the remaining nine babies had a median Apgar score at birth of 9 and a median weight which was 82% of the gestational mean. There were no cases of neonatal bradycardia or respiratory depression and the only case of hypoglycaemia was in a dysmature baby. These findings justify a formal study of beta‐adrenoceptor blocker therapy in hypertensive diseases of pregnancy.

This publication has 4 references indexed in Scilit: